COMP <GO>
LLY vs JNJ // PIOTROSKI F-SCORE QUALITY
Eli Lilly and Company (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LLY 10
— JNJ 4
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
piotroski-score
9/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LLY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LLY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.64% | 67.90% | +15.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.36% | 25.50% | +6.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 36.4x | 18.5x | +17.92 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.30% | 2.97% | -0.67 | JNJ | /fcf-yield <GO> |
| Operating Margin | 40.21% | 34.70% | +5.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 31.90% | 28.50% | +3.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 45.51% | 6.00% | +39.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 0.00% | +0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.29 | 5.59 | +3.70 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 8/9 | +1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.77% | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.6 | 62.1 | +4.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.51 | 1.08 | -0.57 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.6x | 23.0x | +7.62 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29T | $662.49B | $630.65B | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LLY REV | JNJ REV | LLY GROSS % | JNJ GROSS % | LLY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.18B | $94.19B | 83.0% | 67.9% | $16.81B | $19.70B |
| FY 2024 | $45.04B | $88.82B | 81.3% | 69.1% | $8.82B | $19.84B |
| FY 2023 | $34.12B | $85.16B | 79.3% | — | $4.24B | $18.96B |
| FY 2022 | $28.54B | — | 76.8% | — | $7.59B | — |
| FY 2021 | $28.32B | — | 74.2% | — | $7.37B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LLY // BETA 0.51
JNJ // BETA 1.08